Sherbrooke Park Advisers LLC Fennec Pharmaceuticals Inc. Transaction History
Sherbrooke Park Advisers LLC
- $215 Billion
- Q1 2025
A detailed history of Sherbrooke Park Advisers LLC transactions in Fennec Pharmaceuticals Inc. stock. As of the latest transaction made, Sherbrooke Park Advisers LLC holds 17,879 shares of FENC stock, worth $165,201. This represents 0.05% of its overall portfolio holdings.
Number of Shares
17,879
Previous 21,689
17.57%
Holding current value
$165,201
Previous $137 Million
20.57%
% of portfolio
0.05%
Previous 0.04%
Shares
4 transactions
Others Institutions Holding FENC
# of Institutions
72Shares Held
14.1MCall Options Held
10KPut Options Held
83.8K-
Southpoint Capital Advisors LP New York, NY4.08MShares$37.7 Million0.72% of portfolio
-
Sonic Gp LLC Honolulu, HI2.41MShares$22.2 Million33.54% of portfolio
-
Solas Capital Management, LLC Darien, CT2.25MShares$20.8 Million9.62% of portfolio
-
Black Rock Inc. New York, NY1.19MShares$11 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA967KShares$8.94 Million0.0% of portfolio
About FENNEC PHARMACEUTICALS INC.
- Ticker FENC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,067,300
- Market Cap $241M
- Description
- Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec...